Waldencast plc’s Obagi Medical brand announced a partnership with the luxury med‑spa network It’s a Secret Med Spa to expand its ALOHA (Aesthetics Leadership with Obagi’s Hyaluronic Acid) real‑world evidence program. The collaboration will give the spa’s clinicians hands‑on experience with Obagi’s FDA‑approved injectable, saypha MagIQ, and will collect structured data across the spa’s 15 locations in Texas, Arizona and Washington, D.C. The ALOHA program, unveiled in January 2026, is designed to translate the clinical safety and efficacy demonstrated in pivotal trials into everyday practice, providing Obagi with robust patient‑outcome data that can support future product launches and strengthen its position in the U.S. dermal‑filler market.
The partnership is the first new collaboration announced for Obagi Medical since the September 2025 FDA approval of saypha MagIQ. By partnering with a high‑end, luxury med‑spa network, Obagi aims to generate data that could inform pricing, marketing, and clinical guidelines for its broader aesthetics portfolio. The company projects that this expansion could double its addressable market to approximately $4.2 billion by 2029, underscoring the strategic importance of the RWE program in capturing market share in a crowded HA filler landscape that includes Allergan, Galderma, Revance and Evolus.
Management highlighted the strategic rationale behind the partnership. Drew Fine, U.S. General Manager of the Professional Channel, said, “Partnering with It’s a Secret Med Spa is a clear statement of our intent to launch this new injectable on a foundation of robust clinical evidence, education, and integrated patient outcomes. The ALOHA collaboration with It’s a Secret brings together luxury clinical expertise, exceptional patient experience, and a shared passion for delivering extraordinary results — reinforcing Obagi’s commitment to supporting high‑performing practices of all models and helping elevate the standard of care across the premium med‑spa landscape.”
Michel Brousset, co‑founder and CEO of Waldencast, added, “This milestone represents an exciting advancement in our long‑term strategy to become the world’s leading dermatological megabrand at the crossroads of skincare and medical aesthetics with the addition of a comprehensive integrated aesthetic solution that builds upon Obagi Medical’s efficacious skincare products and strengthens our leadership in medical‑grade beauty and aesthetics.” He also noted, “The launch of this product is a catalyst for our growth as we focus on delivering synergistic skincare and injectable offerings under the trusted Obagi Medical brand.”
The partnership leverages saypha MagIQ’s proprietary MACRO Core Technology, which delivers consistent gel distribution and predictable injection and swelling profiles. By collecting real‑world data across multiple high‑volume locations, Obagi can validate the product’s performance in diverse patient populations, a key factor for future regulatory submissions, pricing strategies and market expansion. The RWE program is expected to provide the evidence base that will differentiate Obagi in a market dominated by established HA fillers and support the company’s broader goal of becoming a megabrand that integrates skincare and medical aesthetics.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.